Silver Book Fact

An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.

Jaglal S, Weller I, Mamdani M, et al. Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the hip fracture projections wrong?. Arch Intern Med. 2005; 159(11): 1215-20. http://www.ncbi.nlm.nih.gov/pubmed/15883628

Reference

Title
Population Trends in BMD Testing, Treatment, and Hip and Wrist Fracture Rates: Are the hip fracture projections wrong?
Publication
Arch Intern Med
Publication Date
2005
Authors
Jaglal S, Weller I, Mamdani M, et al
Volume & Issue
Volume 159, Issue 11
Pages
1215-20
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Raloxifene, a selective estrogen receptor modulator (SERM) has been shown to increase vertebral bone mineral density (BMD) by 2% to 3% after 3 years.  
  • Risedronate, a bisphosphonate, has been shown to reduce vertebral fractures by around 41%, hip fractures by 30%, and non-vertebral fractures by 39%.  
  • Treatment with bisphosphonates are highly cost-effective in women over the age of 70 with osteoporosis and a previous fracture.  
  • A meta-analysis of clinical trials found that calcium supplements reduced the risk of vertebral fractures by around 23%.  
  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…